公开(公告)号：EP1805179A2

公开(公告)日：2007-07-11

申请号：EP05857949.1

申请日：2005-09-27

申请人： Bristol-Myers Squibb Company

发明人： ZHAO, Rulin ,  CHEN, Bang-Chi ,  WANG, Bei ,  ZHANG, Huiping

IPC分类号： C07D471/16

CPC分类号： C07D487/04 ,  C07D471/04

摘要： A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4­ c]pyrid-2-ones of the type shown below, as well as the corresponding pyrazoles, from appropriate phenyl hydrazines is described. O (R2b) 0-2 R1 I I 1 1-a X2 N N-,Ra'­ IV These compounds can be useful as factor Xa inhibitors.

公开(公告)号：EP1819703A1

公开(公告)日：2007-08-22

申请号：EP05805620.1

申请日：2005-09-27

申请人： Bristol-Myers Squibb Company

发明人： GLEESON, Margaret M. ,  MCGEORGE, Gary ,  CHEN, Bang-Chi ,  ZHANG, Huiping ,  MALLEY, Mary F. ,  DIMARCO, John D. ,  MURPHY, Denette K. ,  YIN, Xiaotian S. ,  FABIAN, Steven R. ,  GUPTA, Jasmine M.

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P7/02

CPC分类号： C07D471/04

摘要： The instant invention provides crystalline forms of 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1(2H)pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.

公开(公告)号：EP1836209A1

公开(公告)日：2007-09-26

申请号：EP05849629.0

申请日：2005-12-14

申请人： Bristol-Myers Squibb Company

发明人： DELMONTE, Albert J. ,  DHAR, T. G. Murali ,  GALELLA, Michael ,  GLEESON, Margaret ,  GOUGOUTAS, Jack Z. ,  MCLEOD, Douglas D. ,  ZHANG, Huiping ,  CHEN, Bang Chi

IPC分类号： C07D487/10 ,  A61P37/06 ,  A61P19/02

CPC分类号： C07D487/10

摘要： The invention provides crystalline forms of 6-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]nicotinic acid, its pharmaceutically acceptable salts, or solvates, thereof Further, a process is provided for preparing substituted spiro-hydantoin compounds of the formula I, wherein Z is N or CR4b; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; A1, A2, G, and Q are linkers; and R2, R4a, R4c, and R16 are defined in the specification. The process includes the reaction of N-substituted glycine compound and methylene precursor compound with an alkene compound. The substituted spiro-hydantoin compounds of formulae I and II are useful in the treatment of immune and/or inflammatory diseases.

公开(公告)号：EP1805178A2

公开(公告)日：2007-07-11

申请号：EP05858179.4

申请日：2005-09-27

申请人： Bristol-Myers Squibb Company

发明人： SHAPIRO, Rafael ,  ROSSANO, Lucius T. ,  MUDRYK, Boguslaw M. ,  CUNIERE, Nicolas ,  OBERHOLZER, Matthew ,  ZHANG, Huiping ,  CHEN, Bang-chi

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones of the type shown below from appropriate phenyl hydrazines is described. These compounds can be useful as factor Xa inhibitors.

公开(公告)号：EP1805176A2

公开(公告)日：2007-07-11

申请号：EP05805626.8

申请日：2005-09-27

申请人： Bristol-Myers Squibb Company

发明人： MUDRYK, Boguslaw, M. ,  CUNIERE, Nicolas ,  HSIEH, Dau-Ming ,  ROSSANO, Lucius ,  LIANG, Jing ,  CHEN, Bang-Chi ,  ZHANG, Huiping ,  ZHAO, Rulin ,  WANG, Bei ,  DAVID, Adrian

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P7/02

CPC分类号： C07D471/04

摘要： A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones of the type shown below from appropriate phenyl hydrazines is described. Formula (I). These compounds can be useful as factor Xa inhibitors.